8-K: Aptevo and Alligator Bioscience Announce Positive Interim Data for Cancer Drug ALG.APV-527

Aptevo Therapeutics and Alligator Bioscience reported positive interim results from a Phase 1 trial of their cancer drug, ALG.APV-527, showing favorable drug exposure and early signs of clinical activity.

Summary

• Aptevo Therapeutics and Alligator Bioscience have announced positive interim data from the dose escalation phase of their Phase 1 trial for ALG.APV-527, a drug targeting solid tumors expressing the 5T4 antigen.
• The trial, which is over 50% enrolled, has shown that the treatment is generally well-tolerated, and a maximum tolerated dose has not yet been reached.
• The drug was measurable in all patients, with plasma concentrations consistent with the administered dose, and biomarker analysis confirmed the expression of the targets 4-1BB and 5T4.
• Two heavily pre-treated breast cancer patients showed signs of clinical activity, with measurable drug levels and reproducible elevation of serum pharmacodynamic markers, achieving a best overall response of stable disease.
• The trial is progressing to higher dose ranges, with the belief that this may lead to increased clinical activity based on preclinical models.
• The study includes patients with various tumor types, including breast, pancreatic, non-small cell lung cancer, and colorectal cancer, which is expected to provide valuable insights for later-stage development.
• There is growing enthusiasm among clinical sites, with a waiting list of patients wanting to participate in the study.
• The trial is a multi-center, multi-cohort, open-label study with six dose levels, conducted at up to 10 sites in the U.S.

Sentiment

Score: 8

Explanation: The document presents positive interim data from a Phase 1 trial, indicating promising early results and a positive outlook for the drug's development. The language used is optimistic and encouraging, suggesting a high level of confidence in the drug's potential.

Positives

• The drug, ALG.APV-527, was well-tolerated by patients in the trial.
• The drug showed measurable levels in all patients, indicating successful drug exposure.
• Biomarker analysis confirmed the drug's biological activity by showing the expression of the targets 4-1BB and 5T4.
• Early signs of clinical activity were observed in heavily pre-treated breast cancer patients.
• The trial is progressing to higher dose ranges, which may lead to increased clinical activity.
• There is growing enthusiasm among clinical sites, with a waiting list of patients wanting to participate.

Risks

• The trial is still in its early stages, and the results are interim.
• The maximum tolerated dose has not yet been determined, and further dose escalation is ongoing.
• The long-term efficacy and safety of the drug are still unknown.
• The final trial results may vary from the preliminary or interim assessments.
• There are risks associated with clinical development, including unexpected safety issues.
• The success of the drug is dependent on regulatory approvals and market acceptance.

Future Outlook

The companies anticipate announcing additional data later in the year and believe that continued analysis of the cross section of tumor types will offer important insights about ALG.APV-527 that can be used to increase success in later stage development.

Management Comments

• Dirk Huebner, MD, Chief Medical Officer at Aptevo, stated that they are now dosing cohort four, heading into higher dose ranges where they believe there is potential for increased signs of clinical activity.
• Sumeet Ambarkhane, MD, CMO at Alligator Bioscience, expressed excitement about the positive interim data and the potential of their novel bispecific antibody to treat multiple indications.

Industry Context

This announcement is part of the broader trend in the biotechnology industry focusing on developing novel immunotherapies, particularly bispecific antibodies, for cancer treatment. The positive interim data suggests that ALG.APV-527 could be a promising candidate in this field.

Comparison to Industry Standards

• The development of bispecific antibodies like ALG.APV-527 is a growing area in cancer immunotherapy, with companies like Amgen (Blincyto), Roche (Hemlibra), and Regeneron (Libtayo) having already brought similar therapies to market.
• The focus on 4-1BB agonists is also a key area of research, with other companies like Bristol Myers Squibb and Pfizer exploring similar approaches.
• The interim results of ALG.APV-527, showing measurable drug levels and early signs of clinical activity, are comparable to other early-stage trials of similar therapies.
• The trial's design, using a 3+3 dose escalation approach, is a standard practice in early-phase clinical trials.

Stakeholder Impact

• Shareholders may react positively to the positive interim data.
• Employees of both companies may be encouraged by the progress of the drug development.
• Patients with solid tumors may have a new potential treatment option.
• The results may attract potential partners or investors.

Next Steps

• The trial will continue with dose escalation in higher dose ranges.
• Further analysis of the cross section of tumor types will be conducted.
• Additional data will be announced later in the year.

Key Dates

Keywords

ALG.APV-527, bispecific antibody, cancer immunotherapy, solid tumors, 5T4 antigen, 4-1BB agonist, clinical trial, dose escalation, Aptevo Therapeutics, Alligator Bioscience